Insights - Pfizer (PFE) announced plans to buy injectable generics & biosimialar developer Hospira (HSP) at $90/share, for an enterprise value of $17 billion. Hospira closed Wednesday at $64.80.
Read NowInsights - Merck (MRK) revealed on Wednesday that the U.S. FDA has rescinded a Breakthrough Therapy Designation for its investigational Hepatitis C treatment.
Read NowInsights - Spark Therapeutics (ONCE) lists publicly today, joining companies like bluebird bio (BLUE) and Avalanche (AAVL) as yet another emerging gene therapy player.
Read NowInsights - Intercept Pharmaceuticals (ICPT) added over $1 billion to its value in late trading when its lead drug received a Breakthrough Therapy Designation
Read NowInsights - Across the market, multinational companies are blaming missed earnings and lower-than-expected 2015 guidance on foreign exchange effects and cheap oil.
Read NowInsights - That's what Regeneron (REGN) and Sanofi (SNY) paid for a FDA Priority Review Voucher that will shorten the review time for the PCSK9 inhibitor, alirocumab.
Read NowInsights - The trial was successful, with enzalutamide improving progression-free survival (PFS) meaningfully compared to bicalutamide.
Read Now
